Skip to main content

Table 2 Retrospective studies of patients with EGFR ex20ins NSCLC treated with EGFR-TKIs and combination therapy

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Treatment (reference) N Line ORR (%) mPFS (months) mOS (months)
Erlotinib/gefitinib [25] 25 ≥2 8 2 9.5
Afatinib [26] 23 1 8.7 2.7 9.2
Osimertinib 80 mg [27] 6 ≥2 66.7 6.2 NA
Osimertinib 80 mg [28] 15 ≥2 0 3.5 56.3
Osimertinib 160 mg [29] 20 ≥2 25 9.7 NA
Luminespib [30] 29 ≥2 17 2.9 12.8
Afatinib combined with cetuximab [31] 4 ≥2 75 5.4 NA